Cancer Research UK logo.
SearchDonate
  • Search

A study looking at the genetics of lobular carcinoma in situ (GLACIER)

Overview

Cancer types:

Breast cancer

Status:

Results

Phase:

Other

Details

This study looked at genetic changes that may increase the risk of lobular carcinoma in situ (LCIS) or invasive lobular breast cancer. This trial was supported by Cancer Research UK.

LCIS is not cancer but means that there are changes to some of the cells in the breast. Having LCIS increases your risk of getting breast cancer in the future.

In this study, the researchers looked at genetic changes in a large number of women who had been diagnosed with LCIS or a type of breast cancer called invasive lobular breast cancer. They hoped to find out more about the genetic causes.

The aim of the study was to identify genetic changes that may increase the risk of LCIS or invasive lobular breast cancer.

Recruitment start: 11 June 2007

Recruitment end: 31 December 2011

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Rebecca Roylance

Dr Elinor Sawyer

Supported by

Breast Cancer Campaign

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Other information

This is Cancer Research UK trial number CRUK/07/075.

Last reviewed: 29 October 2014

CRUK internal database number: 1013

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.